1,373 research outputs found

    Palaeoenvironment of a mesolithic peat bed from Austin Friars, Leicester

    Get PDF
    A mesolithic peat bed, dated to 9920±100 bp (HAR-4260) (bp = radiocarbon years before the present calculated from A.D. 19S0 within + or - of 100 years in this case. Ed.) was recovered from Austin Friars, Leicester. Analysis of preserved fauna and flora, especially insects and seeds, indicated that the peat had formed in a shallow pond or lake, with vegetated, marshy edges subject to periodic flooding. The pond was set in open countryside characterised by a lack of trees and preponderance of light-demanding species, living in a cold, damp tundra climate at the very end of Late Glacial Zone III (9000-8300 RC.) extending into the Post Glacial (8300-4000 RC.)

    Exploring the Use of Cost-Benefit Analysis to Compare Pharmaceutical Treatments for Menorrhagia

    Get PDF
    Background: The extra-welfarist theoretical framework tends to focus on health-related quality of life, whilst the welfarist framework captures a wider notion of well-being. EQ-5D and SF-6D are commonly used to value outcomes in chronic conditions with episodic symptoms, such as heavy menstrual bleeding (clinically termed menorrhagia). Because of their narrow-health focus and the condition’s periodic nature these measures may be unsuitable. A viable alternative measure is willingness to pay (WTP) from the welfarist framework. Objective: We explore the use of WTP in a preliminary cost-benefit analysis comparing pharmaceutical treatments for menorrhagia. Methods: A cost-benefit analysis was carried out based on an outcome of WTP. The analysis is based in the UK primary care setting over a 24-month time period, with a partial societal perspective. Ninety-nine women completed a WTP exercise from the ex-ante (pre-treatment/condition) perspective. Maximum average WTP values were elicited for two pharmaceutical treatments, levonorgestrel-releasing intrauterine system (LNG-IUS) and oral treatment. Cost data were offset against WTP and the net present value derived for treatment. Qualitative information explaining the WTP values was also collected. Results: Oral treatment was indicated to be the most cost-beneficial intervention costing £107 less than LNG-IUS and generating £7 more benefits. The mean incremental net present value for oral treatment compared with LNG-IUS was £113. The use of the WTP approach was acceptable as very few protests and non-responses were observed. Conclusion: The preliminary cost-benefit analysis results recommend oral treatment as the first-line treatment for menorrhagia. The WTP approach is a feasible alternative to the conventional EQ-5D/SF-6D approaches and offers advantages by capturing benefits beyond health, which is particularly relevant in menorrhagia
    corecore